Zeling Cai

Title: Zeling Cai: Innovator in Antibody Research

Introduction

Zeling Cai is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biotechnology. He has been instrumental in developing innovative solutions that address critical health challenges, particularly in cancer treatment.

Latest Patents

Cai holds four patents, with his latest innovations focusing on antibody-based therapies. One of his notable patents is the "Antibody-TNF α fusion protein and its preparation and applications." This patent describes a fusion protein that combines an antibody moiety with a TNFα moiety, along with methods for its production and applications in tumor prevention and treatment. Another significant patent is for "CTLA-4 antibodies and uses thereof," which details human antibodies that specifically bind to human CTLA-4, along with related pharmaceutical compositions and therapeutic methods.

Career Highlights

Throughout his career, Zeling Cai has worked with Shanghai Kanda Biotechnology Co., Ltd., where he has contributed to various research projects and innovations. His work has been pivotal in advancing the understanding and application of antibody therapies in clinical settings.

Collaborations

Cai has collaborated with notable professionals in the field, including Yi Chen and Heng Wu, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Zeling Cai's work in antibody research exemplifies the innovative spirit of modern biotechnology. His patents and collaborations continue to pave the way for advancements in cancer treatment and therapeutic applications.